OHSU Knight Cancer Institute

Annual Hematology and Breast Cancer Update

Stock photo of Mt. Hood and Portland at sunrise with a pink sky

New date: April 15-16, 2022

Embassy Suites by Hilton Portland Downtown

About the symposium

The Annual Hematology and Breast Cancer Update is a multiple-day course designed for hematologists and oncologists in clinical practice. Our faculty will review and provide updates on a wide range of current topics in hematology and breast cancer therapy. 

April 15

  • 8-9 a.m.: Acute Leukemia Update, guest speaker Curtis Lachowiez, M.D., MD Anderson Cancer Center
  • 9-9:45 a.m.: CML/Mastocytosis Update, Thomas DeLoughery, M.D., Michael Heinrich, M.D.
  • 9:45-10:30 a.m.: Chronic Lymphocytic Leukemia Update, Stephen Spurgeon, M.D.
  • 10:45-11:15 a.m.: General Hematology Update, Thomas DeLoughery, M.D.
  • 11:15 a.m.-noon: Myelodysplasia Update, Elie Traer, M.D., Ph.D.
  • 1:15-2 p.m.: Myeloma Update, Rebecca Silberman, M.D.
  • 2-3 p.m.: Lymphoma Update, Andy Chen, M.D., Ph.D., Craig Okada, M.D.
  • 3:15-4 p.m.: Myeloproliferative Neoplasms Update, Joe Shatzel, M.D.
  • 4-4:30 p.m.: Integration of Palliative Care for Patients with Acute Myeloid Leukemia, Jason Webb, M.D.
  • 4:30-5:15 p.m.: Updates on Stem Cell Transplantation and the Emergence of Cellular Therapy, Richard Maziarz, M.D.

April 16

  • 8-8:45 a.m.: Update in Hemostasis, Kristinia Haley, D.O.
  • 8:45-9:30 a.m.: Thrombosis and Anticoagulation Update, Thomas DeLoughery, M.D.
  • 9:30-10 a.m.: Update in Transfusion, Mandy VanSandt, D.O.
  • 10:15 a.m.-12:30 p.m.: Breast Cancer Review, Zahi Mitri, M.D., Evie Hobbs, M.D.

The course objectives are to increase participant's knowledge of most current management and research in treatment of hematologic diseases and breast cancer.

At the conclusion of the activity, participants will be able to:

  • Integrate the newer therapies into their treatment course.
  • Select the best agent for initial treatment of CML as well as those with sub-optimal responses.
  • Decide how long to treat patients with venous thrombosis.
  • Describe developments in new agents for myeloproliferative syndromes and new findings from the 2019 American Society of Hematology Meeting and the 2019 San Antonio Breast Cancer Meetings.
  • Select the best agent for initial treatment of CML as well as those with sub-optimal responses.
  • Hematologists
  • Oncologists
  • Related health care professionals

Registration to attend:

  • No charge for OHSU medical professionals and students
  • $182.72 for non-OHSU medical professionals and students

Pharma exhibitors, includes two tickets: $1,554.09

Pharma non-exhibiting industry representatives: $286.22

For more information, please contact us at knightevents@ohsu.edu or call 503-396-2947.